AIInvestment
-
Stop Treating Marvell and Bausch Like the Same Bet
Jim Cramer gave his take. Fine. But if you’re putting real money to work, you need more than TV conviction. Marvell and Bausch Health sit on opposite ends of the risk spectrum—one riding the AI buildout, the other crawling out from under a mountain of debt. The question isn’t whether they’re “good companies.” It’s whether…
-
The Fed’s Pause Is a Litmus Test — Stop Trading Like Cuts Are Guaranteed
The Fed just hit pause — and traders are already picking sides. At its late-January meeting, the Federal Reserve held rates at 3.50%–3.75% after three cuts in late 2025. Officials are signaling two more cuts later this year, but Dallas Fed President Lorie Logan threw cold water on any “cut now” enthusiasm, warning against moving…
-
NBIS Is a High-Voltage Bet on AI’s Spending Spree — And That’s the Point
NBIS Isn’t Just Another AI Stock — It’s a Leveraged Bet on the Entire Buildout If you’re looking for a sleepy AI compounder, keep scrolling. Nebius Group (NBIS) is something else entirely — a high-beta, capital-hungry, execution-or-die wager on the most capital-intensive phase of the AI cycle. And yes, it might be the purest public-market…
-
NBIS Isn’t a Value Trap — It’s a High-Stakes AI Bet With No Safety Net
Is NBIS the next AI infrastructure rocket ship — or the kind of stock that looks brilliant right before it blows up your portfolio? Nebius Group (NBIS) has become one of the market’s most polarizing AI plays. The stock trades around $88 after tripling in 2025, fueled by eye-popping contracts: a $17.4B five-year deal with…
You must be logged in to post a comment.